President and CEO
Radius Health, Inc.
Meeting High Unmet Needs
Robert Ward is well known to his pharmaceutical industry colleagues as a consummate strategic thinker with a depth of experience across both the scientific and commercial landscape. He may soon become known for leading Radius Health towards the submission of its first NDA in the U.S. and MAA in the EU, and subject to favorable regulatory review, its first commercial launch of a potentially important new treatment option for prevention of fracture in postmenopausal women with severe osteoporosis.
As the CEO of Radius Health, Bob and his team are working on completing the Phase III clinical development program for the investigational drug abaloparatide-SC, for potential use in prevention of fracture in postmenopausal osteoporosis. In the recently completed Phase III ACTIVE clinical trial, on the primary endpoint, abaloparatide-SC achieved a statistically significant 86% reduction in new vertebral fractures as compared to placebo, and on the secondary endpoints, as compared to placebo, achieved statistically significant reductions in non-vertebral fracture, clinical fractures, and the time to first incident of non-vertebral fracture of both groups of patients. Radius believes that these results represent the largest fracture reduction ever demonstrated in a clinical trial and hence these data have generated significant interest from the medical and scientific community.
“The U.S. Surgeon General reported that a majority of the patients in the U.S. who experience an osteoporotic fracture are not currently diagnosed with osteoporosis nor prescribed a drug to treat the condition,” Bob explains. “We believe that these high-risk patients could benefit from improvements in diagnosis and treatment.”
Radius Health, though, is far from a one trick pony. The company is also advancing earlier stage investigational agents for potential use in two other disease areas with high unmet medical needs—breast cancer and vasomotor symptoms.
“Radius Health is at an exciting stage in its development as we evolve beyond research and development to commercializing our product candidates,” Bob says. “Our goal is to become a rapidly growing biopharmaceutical company by succeeding in our mission to improve the lives of patients who suffer from debilitating endocrine-mediated diseases, including osteoporosis, breast cancer, and vasomotor symptoms, while reducing the economic burden of these diseases.”